argenx to buy Forte Biosciences for USD 77 a share in USD 2.2 billion deal
ARGX•argenx agrees to all-cash acquisition of Forte Biosciences
argenx agreed to buy Forte Biosciences in an all-cash deal valued at about USD 2.2 billion.
Forte shareholders will receive USD 77 per share, an 86% premium to the VWAP since July 9, 2026.
The acquisition adds Forte’s lead asset FB102, a first-in-class anti-CD122 antibody with Phase 1b data in vitiligo and celiac disease.
The deal is expected to close in Q3 2026; funding will come from argenx cash on hand.
